Date post: | 01-Nov-2014 |
Category: |
Health & Medicine |
Upload: | industry-standard-research |
View: | 357 times |
Download: | 0 times |
Public Knowledge, Perceptions, and
Intentions for Biologic and Biosimilar Medicines
©2013 Industry Standard Research www.ISRreports.com
PREVIEW
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 2
act with confidence
Report Overview
This research was designed to provide pharmaceutical sales, marketing, and brand management with
data to better understand how US patients will make decisions regarding their purchase and use of
biosimilar medications.
Major Sections:1. Executive Summary
2. Medication Decision-makingExplores high-level prescribing activities and reveals patients’ predispositions when making prescription decisions. For example, ISR reveals patients’ likelihood to switch to a generic medication against doctor’s orders, how often they consult a pharmacist regarding drug decisions, and how often they request a generic alternative.
3. Biologic and Biosimilar Prescription Choice ModelsISR analyzes the level of importance patients place on several prescription medication attributes, including: Cost, Doctor recommendation, Manufacturing location, Similarity to the original product, Manufacturer, and Safety record.
To test the impact basic biosimilar education has on patient beliefs and intentions, ISR split the sample into two groups: one that received a brief definition of the difference between biologic and chemical medications and one that did not receive the definition.
4. High-level Medication PerceptionsReveals patients’ perceptions surrounding “simple” and “complex” medications. For example, ISR explores patients’ perceptions of medication safety and effectiveness, attributes they associate with “complex” medications, and the use and manufacturing of “simple” generic medications.
5. Perceptions of Biologic and Biosimilar Medications Quantifies patients’ familiarity with and feelings towards biologic medicines.
6. Pharmaceutical Industry PerceptionsMeasures patients’ trust of drug manufacturers by geographic location and reports pharmaceutical company-level brand familiarity.
345 US Respondents
144 Charts and Graphs
97Pages
• Identify product attributes that have the greatest impact on patients’ medication decisions
• Learn which patient segmentations are likely to need additional generics and biosimilars education
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 3
act with confidence
Valuable for:
Respondent Demographics that mirror U.S. population:
# of drugs taken in past 6 months
Health insurance coverageAge
15%, 18-24
26%, 25-35
27%, 36-45
17%, 46-55
8%, 56-65
8%, Over 65 years
39%,4 or more
61%,1-3
48%
24%
14%
Employer
Medicare
Medicaid
• Marketing• Brand Management• Communications• Public Relations
• Sales• Training• Advertising
What you will learn in this report:• The general public’s knowledge and perceptions of biologic and biosimilar medications
• The effect basic biosimilar education has on perceptions and decision-making
• US population’s current beliefs about generic medicines and how those beliefs differ for “generic” biologics
• Percentage of US population who know whether their own prescription medications are chemical or biologic
How you can use this report:• Establish your biosimilar commercialization strategy by leveraging this insight into
the US population’s knowledge, perceptions, and intentions for use of biologic and biosimilar medicines
• Design biosimilar patient education campaigns rooted in the understanding of patients’ high-level drivers of choice
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 4
act with confidence
Table of Contents
Full table of contents and additional sample pages available in the full preview, free on our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-tentions-for-biologic-and-biosimilar-medicines/
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5
act with confidence
act with confidence
Introduction
www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5
Introduction
Facts: • Biologic medications are very expensive
• Blockbuster biologic drugs are coming off-patent over the next few years
• Biosimilars will not be offered in the United States for generic-like $4 per prescription
• The consumer decision-making process regarding biosimilars will be vastly more complicated than it is for chemical generics
Hypothesis:US patients are relatively naive regarding the medications they take and their understanding of biologic drugs is minimal� Knowledge can impact prescription decision-making�
Impact:If the hypothesis holds, this both affords an opportunity and presents a challenge to setting strategies for pharmaceutical sales, marketing, and advertising� The oncoming wave of biosimilar products in the United States will cause a fundamental shift in the way US patients purchase medications� Successful pharmaceutical sales, marketing, and brand management personnel need to understand why consumers make the choices they do when it comes to these “generic” medicines�
Why do some people take generic medications and others do not? Most people in the United States can get their generic medications at a local Wal-Mart for $4 per prescription, so it seems like a fairly easy economic decision� But there is more to this decision than just economics� Maybe the pharmaceutical company that made their original medication has a well-publicized co-pay card or they offer a fairly inexpensive branded generic option or the consumer doesn’t trust the generic manufacturer or their physician or family member has recommended they stay on the original medication�
So while currently it might make economic sense for a consumer to switch to a generic medication, what happens when the economic gap is not as pronounced? ISR has learned through various research projects that the coming biosimilars will not be offered for $4 per prescription� This research was designed to provide pharmaceutical sales, marketing, and brand management with data to help them understand how US patients will make what ISR believes to be a real decision regarding their purchase and use of biosimilar medications�
Sample Page: Report Introduction
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 6
act with confidence
Sample Page
act with confidence
Medication decision-making
www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 38
Respondents earning less than or equal to $45,000 income in 2012 (19%) are more likely than respondents earning more than $45,000 income in 2012 (9%) to be “extremely likely to switch to the less expensive, general alternative�”
Respondents whose main medication is a biologic product (53%) are more likely than respondents who don’t know the composition of their main medication (22%) and respondents whose main medication type is chemical (25%) to be “extremely likely to stay on the more expensive, doctor-recommended drug�”
Total(N=345)
<$45,000(N=152)
F
>$45,000(N=193)
G
Extremely likely to stay on the more expensive, doctor-
recommended drug
29% 26% 32%
Somewhat likely to stay on the more expensive, doctor-
recommended drug
37% 32% 40%
Somewhat likely to switch to the less expensive, generic alternative
21% 23% 19%
Extremely likely to switch to the less expensive, generic alternative
13% 19% G
9%
Total(N=345)
Biologic(N=66)
J
Chemical(N=148)
K
Don’t know(N=131)
L
Extremely likely to stay on the more expensive, doctor-
recommended drug
29% 53% K, L
25% 22%
Somewhat likely to stay on the more expensive, doctor-
recommended drug
37% 36% 36% 37%
Somewhat likely to switch to the less expensive, generic alternative
21% 11% 24% J
22% J
Extremely likely to switch to the less expensive, generic alternative
13% 0% 15% J
18% J
Age
Income level
Main medication type
Willingness to switch to a generic against doctor’s orders: Simple medicationSegment differences
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 7
act with confidence
Sample Page
Full table of contents and additional sample pages available in the full preview, free on our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-tentions-for-biologic-and-biosimilar-medicines/
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 8
act with confidence
Ordering Information
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an un-matched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.
About Industry Standard Research
For pricing and purchasing information, pleas visit our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-tentions-for-biologic-and-biosimilar-medicines/